Empowered Funds LLC Grows Stake in Roivant Sciences Ltd. $ROIV

Empowered Funds LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1,468.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 285,915 shares of the company’s stock after acquiring an additional 267,686 shares during the quarter. Empowered Funds LLC’s holdings in Roivant Sciences were worth $7,920,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its position in Roivant Sciences by 16.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 699,137 shares of the company’s stock valued at $19,366,000 after purchasing an additional 100,622 shares during the last quarter. Maverick Capital Ltd. purchased a new position in Roivant Sciences in the first quarter worth about $45,066,000. Quantinno Capital Management LP raised its holdings in Roivant Sciences by 15.1% in the first quarter. Quantinno Capital Management LP now owns 76,575 shares of the company’s stock worth $2,121,000 after buying an additional 10,064 shares during the last quarter. Waverly Advisors LLC bought a new position in shares of Roivant Sciences in the first quarter worth approximately $348,000. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Roivant Sciences by 64.7% in the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock worth $77,560,000 after buying an additional 1,100,000 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim upped their price objective on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday. Finally, Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Stock Performance

ROIV opened at $33.91 on Friday. The company’s 50-day simple moving average is $32.63 and its two-hundred day simple moving average is $29.05. The stock has a market capitalization of $24.39 billion, a P/E ratio of -56.52 and a beta of 1.11. Roivant Sciences Ltd. has a 52-week low of $10.90 and a 52-week high of $37.00.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $56,376,551.85. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the sale, the director owned 16,474 shares in the company, valued at $566,376.12. This represents a 51.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,055,913 shares of company stock worth $69,639,633 over the last three months. 10.80% of the stock is currently owned by company insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.